The conflict has now reached a binary choice for investors. STAAR CEO Stephen Farrell warned that the activist is attempting ...
STAAR Surgical (STAA) dropped 5% after proxy adviser Glass Lewis recommended holders reject the revised $30.75 a share offer ...
Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we") today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a leading independent proxy advisory firm, has reaffirmed its ...
This week's Medtech in a Minute features news about Teleflex and an update on Alcon's efforts to buy Staar Surgical amid ...
Intro Paragraph** Alcon Inc. (NYSE: ALC) has recently encountered a shift in analyst sentiment, with Julien Ouaddour of BofA Securities downgrading the stock to “Underperform” as of. This rating ...
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses (EVO ICL™) for vision correction, today issued the following statement to ...
Major STAAR shareholders reject Alcon's increased $30.75 bid, citing a flawed sale process, insufficient valuation, and ...
Alcon increases its acquisition offer for STAAR Surgical, emphasizing a final deal amid shareholder debates and delays in the ...
After reviewing the announcements by STAAR and Alcon regarding the course and closing of the 30-day go-shop period, and Alcon's revised offer of $30.75 per share, we remain opposed to the merger even ...
STAAR Surgical's major shareholder intends to vote against the acquisition, stating the price still significantly undervalues ...
The amended offer adds $150 million to Alcon’s original offer of $28 per share, or $1.5 billion, announced back in August.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback